Technical Data
MDR1 (Multi Drug Resistance Protein 1, ABC20, ATP Binding Cassette Subfamily B (MDR/TAP) Member 1, ABCB1, CD243, CLCS, GP170, P-Glycoprotein, P-gp, P Glycoprotein 1, PGY1)
P-glycoprotein is encoded by the MDR1 (ABCB1) gene. It is a member of the ABC superfamily of ATP-binding cassette transporters. Expression of P-glycoprotein is associated with ATP-dependent transmembrane efflux of chemically diverse compounds from the cell. It is the major component of multidrug resistance in human tumors.

Suitable for use in Flow Cytometry, Western Blot, Immunoprecipitation, Immunohistochemistry and Immunocytochemistry. Other applications not tested.

Recommended Dilutions:
Flow Cytometry: Cell permeabilization required
Western Blot: 1:50-1:100
Immunohistochemistry (Paraffin, Frozen): For paraffin sections, dilute 1:25 for biotin based detection. Heat-induced antigen retrieval required. The antibody should be incubated for 60 minutes at RT.
Immunocytochemistry: Cytospin preparations
Optimal dilutions to be determined by the researcher.

Positive Controls:
Cell lines: Appropriate drug-sensitive parental cell lines and their multidrug resistant derivatives prepared by the same methods as the test specimens can be used as control materials.

Tissue: Human liver (positive staining detected along luminal surfaces of bile canaliculi) or human colon (positive staining localized to luminal surface of secretory epithelium) are recommended.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
MabIgG16D562Affinity Purified
500ul-20CBlue IceMouse
Not Determined
SDS-solubilized plasma membranes of a MDR (multidrug resistant) Chinese hamster ovary (CHO) cell line and a human cell line (P08183).
Purified by affinity chromatography.
Supplied as a liquid in PBS, 1% BSA, 0.1% sodium azide.
Recognizes an internal, highly conserved amino acid sequence (VQEALD and VQAALD) found in both protein isoforms, MDR1 P-glycoprotein at ~170kD and MDR3 P-glycoprotein at ~140kD; not species specific. Crossreactivity Proteins: a ~200kD protein which migrates in the same position as myosin and with C-erbB2 protein (p185c-erbB2).
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies: N. Kartner, et al.; Nature 316, 820 (1985). 2. A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines: H.S. Chan, et al.; Lab. Invest. 59, 870 (1988). 3. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies: A.H. Schinkel, et al.; Cancer Res. 51, 2628 (1991). 4. Comparison of an immunoperoxidase "sandwich" staining method and western blot detection of P-glycoprotein in human cell lines and sarcomas: K. Toth, et al.; Am. J. Pathol. 140, 1009 (1992). 5. New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues: K. Toth et al.; Am. J. Pathol. 144, 227 (1994). 6. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations: W.T. Beck, et al.; Cancer Res. 56, 3010 (1996). 7. MRP and MDR1 gene expression in primary breast carcinomas: M. Filipits, et al.; Clin. Cancer Res. 2, 1231 (1996). 8. P-glycoprotein expression and prognostic value in acute myeloid leukemia: L. Senent, et al.; Haematologica 83, 783 (1998). 9. Transport of doxorubicin in mast cell granules and the effect of the calcium antagonist verapamil: L. Candussio, et al.; Anticancer Res. 19, 1101 (1999). 10. Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport: E. Crivellato, et al.; Histochem. J. 31, 635 (1999). 11. Clinical significance of P-glycoprotein (P-gp) expression in childhood acute lymphoblastic leukemia. Results of a 6-year prospective study: C. Dhooge & B. De Moerloose; Adv. Exp. Med. Biol. 457, 11 (1999). 12. The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme: R. Durmaz, et al.; Clin. Neurol. Neurosurg. 101, 238 (1999). 13. Interferon 2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype: M.H. Frank & S. Pomer; J. Cancer. Res. Clin. Oncol. 125, 117 (1999). 14. A multidrug-resistant breast cancer cell line induced by weekly exposure to doxorubicin: S.M. Hahn, et al.; Int. J. Oncol. 14, 273 (1999).15. Characterization of cyclosporin A transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin: K. Kawazu, et al.; Invest. Ophtalmol. Vis. Sci. 40, 1738 (1999). 16. Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein: J.M. van Den Elsen, et al.; PNAS 96, 13679 (1999). 17. Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells: H. Wada, et al.; Exp. Hematol. 27, 99 (1999). 18. Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival: H. Yokoyama, et al.; Surg. Today 29, 1141 (1999). 19. P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries: M. Demeule, et al.; FEBS Lett. 466, 219 (2000). 20. Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity: M. Julien & P. Gros; Biochemistry 39, 4559 (2000). 21. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response: I.O. Ng, et al.; Am. J. Clin. Pathol. 113, 355 (2000). 22. Activation of the human P-glycoprotein ATPase by trypsin: S.L. Nuti, et al.; Biochemistry 39, 3424 (2000). 23. Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart: A. Rosati, et al.; Anticancer Res. 20, 3403 (2000). 24. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies: G.L. Scheffer, et al.; Cancer Res. 60, 5269 (2000)
25. Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis: F. Thevenod, et al.; J. Biol. Chem. 275, 1887 (2000). 26. Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK(1) cell line and its resistant counterpart: G. Decorti, et al.; Biochem. Pharmacol. 61, 61 (2001). 27. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone: R. Yumoto, et al.; Drug. Metab. Dispos. 29, 145 (2001)